1-乙基-4,5-二氧代吡咯烷-3-羧酸乙酯 | 5336-43-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 1-乙基-4,5-二氧代吡咯烷-3-羧酸乙酯
• 英文名称: ethyl 1-ethyl-4,5-dioxopyrrolidine-3-carboxylate
• 英文别名: 1-ethyl-4,5-dioxo-pyrrolidine-3-carboxylic acid ethyl ester；1-Aethyl-4,5-dioxo-pyrrolidin-3-carbonsaeure-aethylester
• CAS: 5336-43-6
• 化学式: C₉H₁₃NO₄
• mdl: MFCD00179693
• 分子量: 199.207
• InChiKey: FEWVUEMINSWDAR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  63.7
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R20/21/22,R36/37/38
• 海关编码：
  2933990090

SDS

Name:	Ethyl 1-ethyl-4 5-dioxopyrrolidine-3-carboxylate 97% Material Safety Data Sheet
Synonym:
CAS:	5336-43-6

Section 1 - Chemical Product MSDS Name:Ethyl 1-ethyl-4 5-dioxopyrrolidine-3-carboxylate 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
5336-43-6	Ethyl 1-ethyl-4,5-dioxopyrrolidine-3-c	97%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 5336-43-6: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 106 - 108 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H13NO4
Molecular Weight: 199.21

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 5336-43-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Ethyl 1-ethyl-4,5-dioxopyrrolidine-3-carboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 5336-43-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 5336-43-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 5336-43-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-乙基-4,5-二氧代吡咯烷-3-羧酸乙酯 在 草酰氯 、 水 、 N,N-二异丙基乙胺 、 sodium hydroxide 作用下， 以 甲醇 、 乙醚 、 二氯甲烷 、 乙腈 为溶剂， 反应 24.5h， 生成 N-(3-(3,4-dichlorophenyl)propyl)-1-ethyl-4-methoxy-5-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide
  参考文献：
  名称：

  [EN] PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS
  [FR] COMPOSÉS DE PYRROLINONE-CARBOXAMIDE UTILES EN TANT QU'INHIBITEURS DE LIPASE ENDOTHÉLIALE

  摘要：

  本发明提供了Formula (I)或Formula (III)的化合物：[在此插入化学结构] (I) [在此插入化学结构] (III)，如规范中定义的，并包括任何这类新化合物的组合物。这些化合物是内皮脂酶抑制剂，可用作药物。

  公开号：

  WO2013048982A1

文献信息

• [EN] PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS<br/>[FR] COMPOSÉS PYRROLINONE CARBOXAMIDE UTILES COMME INHIBITEURS DE LIPASE ENDOTHÉLIALE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2013048928A1

  公开（公告）日：2013-04-04

  The present invention provides compounds of Formula (I): (I), as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments.

  本发明提供了以下式（I）的化合物：（I），如规范中定义的，并包括任何此类新化合物的组合物。这些化合物是内皮酶抑制剂，可用作药物。
• Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
  申请人：Bristol-Myers Squibb Company

  公开号：US08952180B2

  公开（公告）日：2015-02-10

  The present invention provides compounds of Formula (I) or Formula (III): [INSERT CHEMICAL STRUCTURE HERE] (I) [INSERT CHEMICAL STRUCTURE HERE] (III) as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments.

  本发明提供了公式(I)或公式(III)的化合物：[插入化学结构] (I) [插入化学结构] (III)，如规范中所定义，以及包含任何这些新化合物的组合物。这些化合物是内皮细胞脂肪酶抑制剂，可用作药物。
• PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20140213588A1

  公开（公告）日：2014-07-31

  The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments. The disclosure also provides a novel method of treating diseases or conditions related to the activity of endothelial lipase by use of compounds according to Formula (II): as defined in the specification and compositions comprising any of the compounds.

  本发明提供公式(I)的化合物：如规范中定义的和包含这些新化合物的组合物。这些化合物是内皮酯酶抑制剂，可用作药物。本发明还提供了一种使用符合公式(II)的化合物和包含任何这些化合物的组合物来治疗与内皮酯酶活性相关的疾病或病况的新方法。
• PK/PD Disconnect Observed with a Reversible Endothelial Lipase Inhibitor
  作者：Jon J. Hangeland、Lynn M. Abell、Leonard P. Adam、Ji Jiang、Todd J. Friends、Lauren E. Haque、James Neels、Joelle M. Onorato、Alice Ye A. Chen、David S. Taylor、Xiaohong Yin、Thomas W. Harrity、Michael D. Basso、Richard Yang、Paul G. Sleph、David A. Gordon、Christine S. Huang、Ruth R. Wexler、Heather J. Finlay、R. Michael Lawrence

  DOI：10.1021/acsmedchemlett.8b00138

  日期：2018.7.12

  Screening of a small set of nonselective lipase inhibitors against endothelial lipase (EL) identified a potent and reversible inhibitor, N-(3-(3,4-dichlorophenyl)propyl)-3-hydroxy-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxamide (5; EL IC50 = 61 nM, ELHDL IC50 = 454 nM). Deck mining identified a related hit, N-(3-(3,4-dichlorophenyl)propyl)-4hydroxy-1-methyl-5-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide (6a; EL IC50 = 41 nM, EL HDL IC 50 = 1760 nM). Both compounds were selective against lipoprotein lipase (LPL) but nonselective versus hepatic lipase (HL). Optimization of compound 6a for EL inhibition using HDL as substrate led to N-(4-(3,4-dichlorophenyl)butan-2-yl)-1-ethyl-4-hydroxy-5-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide (7c; EL IC50 = 148 nM, ELHDL IC50 = 218 nM) having improved PK over compound 6a, providing a tool molecule to test for the ability to increase HDL-cholesterol (HDL-C) levels in vivo using a reversible EL inhibitor. Compound 7c did not increase HDL-C in vivo despite achieving plasma exposures targeted on the basis of enzyme activity and protein binding demonstrating the need to develop more physiologically relevant in vitro assays to guide compound progression for in vivo evaluation.
• SATO YASUNOBU; SHIMOJI YASUO; FUJITA HIROSHI; MIZUNO HIROSHI; KUMAKURA SE+, YAKUGAKU DZASSI, JAKUGAKU ZASSNI, J. PHARM. SOS. JAR., 1978, 98, NO 4, 44+
  作者：SATO YASUNOBU、 SHIMOJI YASUO、 FUJITA HIROSHI、 MIZUNO HIROSHI、 KUMAKURA SE+

  DOI：——

  日期：——